Ziva D Cooper

Professor-in-Residence, Psychiatry and Biobehavioral Sciences, University of California Los Angeles

Professor-in-Residence, Anesthesiology, University of California Los Angeles

UC Profile
UCLA Center for Cannabis and Cannabinoids

Dr. Ziva Cooper, Ph.D. is the Director of the UCLA Center for Cannabis and Cannabinoids in the Jane and Terry Semel Institute for Neuroscience and Human Behavior and Professor in the UCLA Departments of Psychiatry and Biobehavioral Sciences and Anesthesiology. Her research involves understanding variables that influence both the therapeutic potential and adverse effects of cannabis and cannabinoids, the chemicals in the cannabis plant. Her current projects funded by the NIH and California State include understanding the potential for cannabis constituents to reduce reliance on opioids, differences between men and women in their response to the pain-relieving effects of cannabis, effects of cannabis as a function of age, and therapeutic effects of cannabinoids in patient populations. Dr. Cooper served on the National Academies of Sciences Committee on the Health Effects of Cannabis that recently published a comprehensive report of the health effects of cannabis and cannabinoids. She is the President-elect of the International Cannabinoid Research Society, a past Board Director for the College on Problems of Drug Dependence, an Associate Editor of The American Journal of Drug and Alcohol Abuse and Neuropsychopharmacology, and is on several Editorial Boards of journals including Cannabis and Cannabinoid Research.

Interests

Cannabis and cannabinoids, Clinical trials, Psychopharmacology, Opioids, Substance use disorders

Education and Training

University of MichiganPhD2007Biopsychology

Publications

  1. McManus K, Venegas A, Henry B, Cooper ZD, Grodin EN, Ray LA. The role of sex in daily levels of high-risk alcohol and cannabis co-use.. Drug and alcohol dependence reports, 2023.
  2. Kapler S, Adery L, Hoftman GD, Amir CM, Grigoryan V, Cooper ZD, Bearden CE. Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool.. Psychological medicine, 2023.
  3. Brasky TM, Newton AM, Conroy S, Adib A, Adley NC, Strassels SA, Hays JL, Cooper ZD, Wagener TL, Stevens E, Plascak JJ, Krok-Schoen JL. Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer.. Cancer research communications, 2023.
  4. Assaf RD, Hamad R, Javanbakht M, Arah OA, Shoptaw SJ, Cooper ZD, Gorbach PM. Associations of U.S. state-level COVID-19 policies intensity with cannabis sharing behaviors in 2020.. Research square, 2023.
  5. Farkas DJ, Cooper ZD, Heydari LN, Hughes AC, Rawls SM, Ward SJ. Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy.. Cannabis and cannabinoid research, 2023.
  6. Lake S, Haney M, Cooper ZD. Sex differences in the subjective and reinforcing effects of smoked cannabis.. Addiction biology, 2023.
  7. Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.. Nature medicine, 2023.
  8. Assaf RD, Javanbakht M, Gorbach PM, Cooper ZD. Cannabis Use and Sharing Practices Among Sexual Minority and Heterosexual Individuals During the COVID-19 Pandemic.. LGBT health, 2023.
  9. Meza BPL, Dudovitz RN, Cooper ZD, Tucker JS, Wong MD. Adolescent Cannabis Misuse Scale: Longitudinal Associations with Substance Use, Mental Health, and Social Determinants of Health in Early Adulthood.. Substance use & misuse, 2023.
  10. Murray CH, Javanbakht M, Cho GD, Gorbach PM, Fulcher JA, Cooper ZD. Changes in Immune-Related Biomarkers and Endocannabinoids as a Function of Frequency of Cannabis Use in People Living With and Without HIV.. Cannabis and cannabinoid research, 2023.
  11. Lake S, Cooper ZD, Ong K, Lucas P. Shifts in medical cannabis use in Canada during the COVID-19 pandemic.. Health promotion and chronic disease prevention in Canada : research, policy and practice, 2023.
  12. Assaf RD, Javanbakht M, Gorbach PM, Arah OA, Shoptaw SJ, Cooper ZD. Puff, Puff, Don't Pass: harm reduction for cannabis use during a viral respiratory pandemic.. Harm reduction journal, 2023.
  13. Pabon E, Cooper ZD. Controlled human drug administration studies are necessary to define the THC-sparing effects of CBD and other cannabis constituents.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023.
  14. Murray CH, Haney M, Foltin RW, Manubay J, Bedi G, Cooper ZD. Smoked cannabis reduces peak cocaine plasma levels and subjective effects in a controlled drug administration study of polysubstance use in men.. Drug and alcohol dependence, 2022.
  15. Lake S, Cooper ZD. Understanding Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration in the Era of Legalization.. The American journal of psychiatry, 2022.
  16. Lake S, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ. Methadone Dose, Cannabis Use, and Treatment Retention: Findings From a Community-based Sample of People Who Use Unregulated Drugs.. Journal of addiction medicine, 2022.
  17. Venegas A, Du H, Cooper ZD, Ray LA. Cannabis and alcohol co-use: The effects of intensity of cannabis use among heavy drinkers.. Addictive behaviors, 2022.
  18. Haney M, Bedi G, Cooper ZD, Herrmann ES, Reed SC, Foltin RW, Kingsley PJ, Marnett LJ, Patel S. Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.. Addiction biology, 2022.
  19. First OK, MacGibbon KW, Cahill CM, Cooper ZD, Gelberg L, Cortessis VK, Mullin PM, Fejzo MS. Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum.. Geburtshilfe und Frauenheilkunde, 2022.
  20. Lake S, Assaf RD, Gorbach PM, Cooper ZD. Changes in secondary substance use after the onset of the COVID-19 pandemic among people who use cannabis: Findings from a web-based sample of adults in the United States.. Experimental and clinical psychopharmacology, 2022.
  21. Middlekauff HR, Cooper ZD, Strauss SB. Drugs of Misuse: Focus on Vascular Dysfunction.. The Canadian journal of cardiology, 2022.
  22. Assaf RD, Gorbach PM, Cooper ZD. Changes in medical and non-medical cannabis use among United States adults before and during the COVID-19 pandemic.. The American journal of drug and alcohol abuse, 2022.
  23. Lake S, Assaf RD, Gorbach PM, Cooper ZD. Selective Changes in Medical Cannabis Use Early in the COVID-19 Pandemic: Findings from a Web-Based Sample of Adults in the United States.. Cannabis and cannabinoid research, 2022.
  24. Cooper ZD, Abrams DI, Gust S, Salicrup A, Throckmorton DC. Challenges for Clinical Cannabis and Cannabinoid Research in the United States.. Journal of the National Cancer Institute. Monographs, 2021.
  25. Lake S, Kerr T, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ. The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs.. Cannabis and cannabinoid research, 2021.
  26. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms.. Cannabis and cannabinoid research, 2021.
  27. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans.. British journal of clinical pharmacology, 2021.
  28. Kozak K, H Smith P, Lowe DJE, Weinberger AH, Cooper ZD, Rabin RA, George TP. A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness.. The American journal of drug and alcohol abuse, 2021.
  29. Cooper ZD, Evans SM, Foltin RW. Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates.. Experimental and clinical psychopharmacology, 2021.
  30. Siegel R, Sullivan N, Monte AA, Vargas NM, Cooper ZD, Ma Y, Meltzer AC. Motivational interviewing to treat substance use disorders in the emergency department: A scoping review.. The American journal of emergency medicine, 2021.
  31. Arout CA, Cooper ZD, Reed SC, Foltin RW, Comer SD, Levin FR, Haney M. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.. Addiction biology, 2021.
  32. Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, Cooper ZD, Cyr C, Daeninck P, Deshpande A, Ethans K, Flusk D, Le Foll B, Milloy MJ, Moulin DE, Naidoo V, Ong M, Perez J, Rod K, Sealey R, Sulak D, Walsh Z, O'Connell C. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control.. International journal of clinical practice, 2020.
  33. Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.. Pharmacology, biochemistry, and behavior, 2020.
  34. Venegas A, Meredith LR, Green R, Cooper ZD, Ray LA. Sex-dependent effects of alcohol administration on the urge to use cannabis.. Experimental and clinical psychopharmacology, 2020.
  35. Venegas A, Meredith LR, Cooper ZD, Towns B, Ray LA. Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications.. Alcohol and alcoholism (Oxford, Oxfordshire), 2020.
  36. Lake S, Walsh Z, Kerr T, Cooper ZD, Buxton J, Wood E, Ware MA, Milloy MJ. Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis.. PLoS medicine, 2019.
  37. Cooper ZD, Abrams DI. Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies.. The American journal of drug and alcohol abuse, 2019.
  38. Chao T, Haney M, Cooper ZD, Vadhan NP, Van Dam NT, Van Snellenberg J, Bedi G. Cognitive function in aging cocaine smokers.. Journal of psychopharmacology (Oxford, England), 2019.
  39. Adinoff B, Cooper ZD. Cannabis legalization: progress in harm reduction approaches for substance use and misuse.. The American journal of drug and alcohol abuse, 2019.
  40. Cooper ZD, Adinoff B. Necessity of addressing motivations for cannabis use to guide research.. The American journal of drug and alcohol abuse, 2019.
  41. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.. Addiction biology, 2018.
  42. Bedi G, Hao X, Van Dam NT, Cooper ZD, Rubin E, Vadhan NP, Marino L, Haney M. Social motivational processing and interpersonal function in aging cocaine smokers.. Addiction biology, 2018.
  43. Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR. Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.. Addiction biology, 2018.
  44. Piomelli D, Weiss S, Boyd G, Pacula RL, Cooper Z. Cannabis and the Opioid Crisis.. Cannabis and cannabinoid research, 2018.
  45. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018.
  46. Cooper ZD, Poklis JL, Liu F. Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.. Neuropharmacology, 2017.
  47. Cooper ZD, Craft RM. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017.
  48. Cooper ZD, Johnson KW, Vosburg SK, Sullivan MA, Manubay J, Martinez D, Jones JD, Saccone PA, Comer SD. Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers.. Drug and alcohol dependence, 2017.
  49. Piomelli D, Cooper Z, Abrams D, Grant I, Patel S. A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members.. Cannabis and cannabinoid research, 2017.
  50. Cooper ZD, Haney M. Sex-dependent effects of cannabis-induced analgesia.. Drug and alcohol dependence, 2016.
  51. Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.. Current psychiatry reports, 2016.
  52. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.. Psychopharmacology, 2016.
  53. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015.
  54. Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.. Addiction biology, 2015.
  55. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015.
  56. Balter RE, Cooper ZD, Haney M. Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.. Current addiction reports, 2014.
  57. Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers.. Drug and alcohol dependence, 2014.
  58. Comer SD, Metz VE, Cooper ZD, Kowalczyk WJ, Jones JD, Sullivan MA, Manubay JM, Vosburg SK, Smith ME, Peyser D, Saccone PA. Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.. Behavioural pharmacology, 2013.
  59. Ramesh D, Haney M, Cooper ZD. Marijuana's dose-dependent effects in daily marijuana smokers.. Experimental and clinical psychopharmacology, 2013.
  60. Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013.
  61. Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.. Pain, 2013.
  62. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013.
  63. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013.
  64. Cooper ZD, Foltin RW, Evans SM. Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques.. Hormones and behavior, 2012.
  65. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.. Biological psychiatry, 2012.
  66. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.. Addiction biology, 2012.
  67. Cooper ZD, Sullivan MA, Vosburg SK, Manubay JM, Haney M, Foltin RW, Evans SM, Kowalczyk WJ, Saccone PA, Comer SD. Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers.. Behavioural pharmacology, 2012.
  68. Roux P, Tindall C, Fugon L, Murray J, Vosburg SK, Saccone P, Sullivan MA, Manubay JM, Cooper ZD, Jones JD, Foltin RW, Comer SD. Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health.. Addiction (Abingdon, England), 2012.
  69. Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.. Addiction biology, 2012.
  70. Cooper ZD, Jones JD, Comer SD. Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances.. Expert opinion on investigational drugs, 2012.
  71. Gooch CM, Rakitin BC, Cooper ZD, Comer SD, Balsam PD. Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.. Behavioural pharmacology, 2011.
  72. Cooper ZD, Shi YG, Woods JH. Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats.. Psychopharmacology, 2010.
  73. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.. Psychopharmacology, 2010.
  74. Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers.. Psychopharmacology, 2010.
  75. Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.. Addiction (Abingdon, England), 2010.
  76. Comer SD, Cooper ZD, Kowalczyk WJ, Sullivan MA, Evans SM, Bisaga AM, Vosburg SK. Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers.. Psychopharmacology, 2009.
  77. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats.. Drug and alcohol dependence, 2009.
  78. Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.. Drug and alcohol dependence, 2009.
  79. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.. International review of psychiatry (Abingdon, England), 2009.
  80. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH. A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.. Annals of emergency medicine, 2008.
  81. Cooper ZD, Truong YN, Shi YG, Woods JH. Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat.. The Journal of pharmacology and experimental therapeutics, 2008.
  82. Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.. Addiction biology, 2008.
  83. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper ZD, Woods JH. Cocaine esterase: interactions with cocaine and immune responses in mice.. The Journal of pharmacology and experimental therapeutics, 2006.
  84. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, Woods JH. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase.. Molecular pharmacology, 2006.
  85. Houshyar H, Cooper ZD, Woods JH. Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: a chronic stress paradigm.. Journal of neuroendocrinology, 2001.